Hesitancy to Receive the Booster Doses of COVID-19 Vaccine Among Cancer Patients in China:A Multicenter Cross-Sectional Survey—Four PLADs,China,2022  

作　　者：Yuxiao Wang Lei Zhang Siyu Chen Xinquan Lan Moxi Song Rila Su Jianzhou Yang Zixin Wang Junjie Xu 

机构地区：[1]Clinical Research Academy,Peking University Shenzhen Hospital,Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center,Shenzhen City,Guangdong Province,China [2]Department of Radiotherapy,Peking University Shenzhen Hospital,Peking University,Shenzhen City,Guangdong Province,China [3]JC School of Public Health and Primary Care,Faculty of Medicine,The Chinese University of Hong Kong,Hong Kong,China [4]Department of Epidemiology,China Medical University,Shenyang City,Liaoning Province,China [5]Clinical Research Academy,Peking University Shenzhen Hospital,Shenzhen City,Guangdong Province,China [6]Cancer Center at Inner Mongolia People’s Hospital,Hohhot City,Inner Mongolia Autonomous Region,China [7]John Hopkins Bloomberg School of Public Health,Baltimore,United States [8]Department of Public Health and Preventive Medicine,Changzhi Medical College,Changzhi City,Shanxi Province,China

出　　处：《China CDC weekly》2023年第10期223-228,I0001-I0003,共9页中国疾病预防控制中心周报（英文）

基　　金：This study was supported by the National Natural Science Foundation of China(81872674);the Joint Foundation of Innovative Environment Construction of Autonomous Region of Xinjiang(#2019D01C326);the Four“Batches”Innovation Project of Invigorating Medical Cause through Science and Technology of Shanxi Province(2022XM45);Shenzhen Science and Technology Innovation Committee Projects(No.JCYJ20220818102817038);the Scientific Research Foundation of Peking University Shenzhen Hospital(No.KYQD2022216).

摘　　要：Summary What is already known about this topic?Cancer patients are more vulnerable and have higher mortality rates from severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)than the general population;however,coverage for booster doses of the coronavirus disease 2019(COVID-19)vaccine was low among cancer patients in China.What is added by this report?Overall,32.0%and 56.4%of cancer patients from four Provincial Level Administrative Divisions(PLADs)expressed hesitancy toward the first and second booster doses,respectively.Factors negatively associated with hesitancy to receive booster doses included positive attitudes,perceived support,and higher exposure to COVID-19 vaccination information.Conversely,postvaccination fatigue was positively associated with vaccine hesitancy.What are the implications for public health practice?Improved COVID-19 vaccination coverage is needed to promote health for cancer patients.

关 键 词：doses VACCINE Cancer 

分 类 号：R73[医药卫生—肿瘤] R186[医药卫生—临床医学]